International journal of pharmaceutics
Cure8 research brief
Why This Matters
A rectal 5-ASA gel that forms in place and sticks to the mucosa could reduce leakage and improve drug retention, potentially increasing effectiveness and patient comfort for people using topical therapies for ulcerative colitis.
Who Should Pay Attention
Adult patients with ulcerative colitis who use rectal mesalamine, clinicians prescribing topical UC treatments, and drug-delivery researchers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study describes a pharmaceutical formulation (poloxamer + carbopol) that gels at 30–35°C and is designed for injectable enema delivery of 5-ASA. Lab and animal tests reported slower drug release with higher carbopol, improved retention on porcine mucosa, and greater anti-inflammatory effects in a rat ulcerative colitis model.
The report focuses on formulation properties and preclinical efficacy rather than results from human patients.
Keep In Mind
Findings are from formulation characterization, ex vivo porcine-mucosa testing, and rat models; no human clinical data are reported in the abstract. Translation to clinical practice will require human safety and efficacy trials.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternational journal of pharmaceutics
AuthorsEna Hattanda, Narumi Maida, Kaoru Hirose +12 more
InstitutionFaculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika, Tokyo 125-8585, Japan.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 14, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab.
Autoinjectors can make long-term biologic treatment easier, more convenient, and potentially improve adherence for people with Crohn’s disease or ulcerative colitis who use ustekinumab.
Rectal stump management in paediatric ulcerative colitis—An international survey for the ESPGHAN PORTO IBD group study
The survey highlights wide variation in how rectal stumps are assessed and managed after colectomy in children with UC, indicating uncertainty and a gap in standardised care that could affect outcomes and follow-up...
Sequential Biologic, Small-Molecule, and GLP-1 Analogue Therapy in Postcolectomy Enteritis With High Output Stoma.
People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.